Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Signs Letter of Intent with Large Multinational Pharmaceutical Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Alpha Cognition Inc ACOG

Healthcare Biotechnology
Alpha Cognition Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is engaged in developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Company’s pipeline includes ALPHA-1062, ALPHA-0602, and ALPHA-0702 and ALPHA-0802 (GEMs). The Company’s ALPHA-1062 is a patented new chemical entity being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, with expected minimal gastrointestinal side effects. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI. ALPHA-0602 is a gene therapy program delivering progranulin, a neurotrophic protein. It is in preclinical development for the treatment of ALS.


NDAQ:ACOG - Post by User

Alpha Cognition Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(144)
•••
Post by culturedpiggy01on Jan 04, 2022 11:14am
120 Views
Post# 34281688

$ACOG.v releases packed schedule for January 2022

$ACOG.v releases packed schedule for January 2022
A bunch of exciting news released by $ACOG.v as they’ve announced that they’ll be participating in three investor conferences this January, starting the year super strong! Details below: 
 
LifeSci Advisors Partners Corporate Access Event, January 5-7: $ACOG.v will conduct one-on-one meetings at the event
BIO Partnering at JPM, January 10-14: to be held at the 2022 JP Morgan Healthcare Conference.
H.C. Wainwright 2022 BioConnect Conference, January 10-13: the company will present a virtual presentation (available later on-demand) and also hold one-on-one meetings
 
expecting a lot of new investor traction! 
 
td, $ACOG.v trading at $1.07 with market cap at $65.8 M
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities